In contrast, the FASL-mediated killing mechanism exploited by CAR T cells is strictly regulated, because activation-dependent upregulation of FASL on CAR T cells can only occur at the tumor site upon antigen encounter [1]. This evidence concerns the gene FASLG and neoplasm.